B
e t w e e n 19 8 5 a n d 19 9 9 , as managed care spread nationwide, more practice guidelines were developed for medication treatment. Changes in drug coverage, drug research and development (R&D), faster Food and Drug Administration (FDA) approval, and increased drug marketing to physicians and consumers are likely contributors to increased use of medications in ambulatory care. In this paper I use data from the National Ambulatory Medical Care Survey (NAMCS) to track physicians' use of medications during this period. I describe trends in medication use at or after office visits, including patients' and physicians' characteristics that are related to increased reliance on medications.
Methods
Data in this study are from NAMCS, a multistage probability-based sample survey of 2,500-4,500 office-based physicians conducted by the National Center for Health Statistics (NCHS). NAMCS has collected patient encounter data periodically since 1973 and annually since 1989. For this report I performed a secondary analysis of survey data from 1985, 1989-90, 1995-96, 1997-98, and 1999 . Where possible, two years of data were combined to make the estimates more reliable. A total of 288,941 patient encounter records were used in this analysis. Details on the survey may be found elsewhere. 1 Physicians were asked to complete an encounter form for a sample of approximately thirty patient visits in a randomly assigned one-week reporting period during the survey year. Sample weights were applied to make national estimates of the number and characteristics of office visits. The response rates ranged from 80 percent in 1985 to 63 percent in 1999. Because NAMCS estimates are based on a sample of physician encounters, they are subject to sampling error. Standard errors were computed using SUDAAN, which takes the complex sample into consideration. 2 State-ments about significance are based on a weighted least-squares regression of estimates since 1985. The average relative standard error for the estimates presented here is .09. A multiple logistic regression analysis was performed using SUDAAN on the 1985 and 1999 data to model multiple prescribing events at office visits. The patient record form is used to collect data on patients' characteristics such as age, sex, and race and on visit characteristics such as diagnosis, services provided, and medications prescribed. Physicians record all new or continued medications ordered, supplied, or administered at the visit, including prescription and nonprescription preparations, immunizations, desensitizing agents, and anesthetics. The maximum number of medications collected during the survey history varied from five to eight. This analysis used the first five drug mentions. Therapeutic class was assigned to the drug mentions based on the 1995 edition of the National Drug Code Directory (NDC). 3 In this analysis drugs classified in multiple categories are tabulated under the first category only. A report describing the method and instruments used to collect and process drug information has been published elsewhere. 4 I present unadjusted rates here because no significant differences appeared between drug mention rates that were ageadjusted and those that were not.
Results
The annual number of visits to office-based physicians increased 19 percent, from 636.4 million in 1985 to 756.7 million in 1999. The number of drug mentions during this time period increased 59 percent, from 693 million to 1.1 billion, with a resulting 34 percent increase in the drug mention rate from 109 to 146 drugs per 100 visits. The increase in drug mention rates was found for all age groups and all physician specialties except general surgeons, cardiologists, and dermatologists (Exhibit 1). The largest increase was found for psychiatrists, whose drug mention rate increased from 82 to 178 drugs per 100 visits. The distribution of visits to these specialties varied over time, as did some of the more common chronic diagnoses that are treated with medication therapy. The percentage of visits for hyperplipidemia and related lipoid disorders (such as high cholesterol and high triglycerides) had the largest increase (Exhibit 2). The number of medications at the selected chronic disease visits shown in the exhibit also increased.
Increases were found for all of the major therapeutic classes, with the notable exception of antimicrobial agents, which declined 12 percent. The penicillins and tetracycline led the decline, and there was an increase in quinolones-broad-spectrum antibiotics used to treat gastrointestinal, urinary tract, and lower respiratory tract infections. Six therapeutic classes account for 80 percent of the increase in the overall drug mention rate: central nervous system drugs, hormones, respiratory drugs, pain relief drugs, metabolics/nutrients, and cardiovascular-renal drugs (Exhibit 3).
At a more detailed level, nine classes account for 75 percent of the observed increase (Exhibit 4). Increases in antidepressants alone account for 13.5 percent of the observed increase during the study period. Other classes contributing the most include lipid-lowering drugs and drugs to treat hypertension and diabetes. For comparability in this analysis, current therapeutic classes were assigned to 1985 drug mentions, because the 1995 NDC classification has more four-digit classes than there were in 1985.
Drug mention increases varied by patient's age and therapeutic class (Exhibit 5). While the drug mention rate increased for almost all therapeutic classes for seniors, the largest increase was found for hematologic agents (187 percent, from 1.9 to 5.5 mentions per 100 visits). The largest increase observed for patients ages 45-64 was 109 percent for metabolics (from 4.8 to 10.0 mentions), which includes lipid-lowering drugs such as Lipitor. Neurologic agents also showed a large increase among persons in this age group (from 1.6 to 2.6 mentions) and among those ages 25-44 (from 2.4 to 4.7 mentions). Central nervous system drugs including selective serotonin reuptake inhibitors (SSRIs) had the largest in-2 0 8 J u l y /A u g u s t 2 0 0 2 H e a l t h T r a c k i n g crease for patients ages 15-24 (130 percent, from 3.8 to 8.8 mentions). The therapeutic class with the largest increase for children was also central nervous system drugs, which increased 327 percent (from 1.1 to 4.5 mentions). Among the most frequently mentioned drugs in this class for children's visits in 1999 was Ritalin for treating attention deficit hyperactivity disorder (ADHD).
The percentage of physician office visits with at least one medication mentioned increased by only 8 percent, from 61.2 to 66.2 percent of visits. This was driven by an increase for patients ages 25-44. Multiple drug prescribing accounted for the largest part of the increase (Exhibit 6). Overall, the percentage of visits with two or more drugs increased 39 percent. A similar increase was found for each age group studied.
A multiple logistic regression analysis modeled factors influencing multiple prescriptions among drug visits (for visits with any medications prescribed): patient's age, expected source of payment, number of diagnoses, and physician's specialty. Number of diagnoses at the visit measures comorbidity, which is related to the number of drugs prescribed. 5 Visits by persons with multiple conditions are more likely to require multiple medications. 
Discussion
The NAMCS data examined here show increased use of medications since 1985 for all age groups, most specialties, and most therapeutic classes. The magnitude of the increases for specific therapeutic classes varied by age group. While one assumption is that increased medication use is due to aging of the population, differences in the proportions of middleage and senior patients during this time period account for only about 20 percent of the observed increase in overall drug mention rates. In 1985 patients age forty-five and older represented 42.1 percent of physician office visits. 6 In 1999 they represented 52.1 percent. 7 Adjusting the 1999 drug mention rate to the 1985 age distribution of office visits still leaves a 28 percent increase in drug mention rates.
Another potential explanation is that doctors may be treating patients who, in general, have more comorbidities than in the past. The NAMCS data show that the relative proportion of visits with three diagnoses more than doubled during the study period. About half of the observed increase in drug mention rates can be explained by this change in case-mix.
The percentage of visits with multiple drug mentions increased from 45.3 percent in 1985 to 58.1 percent in 1999, an overall increase of 28 percent. The logistic regression model shows that after differences in the distribution of visits by patients' age, number of diagnoses, source of payment, and physician specialty are adjusted for, physicians were 43 percent more likely to prescribe multiple drugs in 1999 than in 1985. Examining other factors in the model also shows interesting evidence leading to multiple prescribing. Visits with government payment sources were more likely to receive multiple drugs (Medicare, odds ratio = 1.24; Medicaid, odds ratio = 1.44). Since these odds ratios are adjusted for differences in patients' age and number of diagnoses, this may indicate that these patients are more likely to have con- The remainder of the observed increase could be driven by several factors, including the development of newly formulated drugs to treat chronic conditions, increased health insurance and prescription drug coverage, increased focus by physicians and health plans on managing health care, and direct-toconsumer marketing of drugs.
n New drugs. FDA approvals have doubled since the early 1980s, from an average of about nineteen per year to thirty-eight in the late 1990s. 8 Also, the length of time for approval of new drugs declined from about thirty-three months in 1986 to twelve months in 1998. This trend coincides with increased R&D by pharmaceutical companies. There were 104 new molecular entities (NMEs) approved between 1997 and 1999, many of which are used to treat chronic conditions. They accounted for 3.7 percent of all drug mentions in 1999. 9 For example, among lipid-lowering 2 1 2 J u l y /A u g u s t 2 0 0 2 H e a l t h T r a c k i n g 13 As managed care made inroads into Medicare during the early 1990s, a higher proportion of seniors chose a plan option that provided some prescription drug benefit. To be competitive, many plans increased their drug coverage. More than half of all Medicare recipients now have some kind of drug coverage from supplemental plans. 14 Studies have shown that the likelihood of having drug coverage is directly related to the number of prescriptions a person needs. 15 The increased probability of filling a prescription may be related to physicians' choice of medication over other therapies.
The data from this study indicate that the drug mention rate increased at the same rate for all payment sources. If the 1999 visits were distributed like the 1985 visits with regard to source of payment, the same level of increase in total drug mention rate would have been observed. The effect of managed care on drug prescribing may be more subtle. Increased emphasis on managed care has also likely led to increased use of treatment guidelines, many of which included medical consensus on medication use. The proliferation of practice guidelines developed and supported by third-party payers would help to explain the increased reliance on medication therapy. For example, treatment guidelines for hypertension include multiple drug regimens in many cases. 16 Similarly, there has been an increased emphasis on medications for pain relief. 17 While approximately one-quarter of office visits include mention of the patient's pain, the relative percentage of those visits that included mention of a pain medication increased 21 percent, from 24 percent of visits in 1985 to 29 percent in 1999 (data not shown). The percentage of visits with no direct pain complaint that had a mention of pain medication increased from 6 percent to 9 percent during the study period (data not shown).
n DTC advertising. Direct-to-consumer (DTC) advertising for prescription drugs blossomed in 1997 after the FDA clarified rules pertaining to ads, making it easier to launch television, print, and radio ad campaigns. Such increased mass-media advertising has coincided with a sharp rise in the number of prescriptions written and overall spending on prescription drugs. Doctors wrote 34 percent more prescriptions in 1999 than in 1998 for the twenty-five DTC-promoted drugs that contributed most to overall drug spending, while they wrote only 5 percent more prescriptions for all other prescription drugs. 18 For example, Pfizer increased DTC advertising for Lipitor sixfold between 1998 and 1999 and saw prescriptions increase by 50 percent. Of course, pharmaceutical companies may have chosen to apply DTC advertising to the new drugs that were expected to have the most use. Nevertheless, as DTC advertising has increased over the years, so has the number of medications prescribed increased, whether DTC advertising motivates patients to come to the doctor or
